Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium Showcasing Advancements in Breast Cancer Risk Assessment and Treatment
SALT LAKE CITY, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN) a leader in genetic testing and precision medicine, today announced multiple presentations of new data at the 2022 San Antonio Breast Cancer Symposium (SABCS), including a spotlight discussion on breast cancer risk prediction.
“Genetic testing is an essential tool across the continuum of breast cancer care, enabling physicians to provide guidance about a woman’s individual risk and helping them make personalized treatment recommendations upon diagnosis,” said Thomas Slavin, M.D., chief medical officer, Myriad Genetics. “The data we’re presenting demonstrates our ongoing commitment to advancing scientific research to improve patient outcomes and delivering products that provide timely, data-driven medical information to support equitable care for all women.”
Myriad Data at SABCS 2022
Spotlight Discussion: PD14-05 - Prospective longitudinal validation of a breast cancer risk prediction model in a cohort of 130,058 women
Poster Session: P2-03-23 - Retrospective evaluation of outcomes in a real-world, prospective cohort using EndoPredict®: Results from the Charité registry
Additionally, there will also be poster session (P6-01-24) about an independent EndoPredict study from Klinikum rechts der Isar, Technical University of Munich, Germany, on Friday, Dec. 9 from 7:00-8:15 a.m. CST. The study looked at prospective long-term outcome data with EndoPredict for women with early-stage breast cancer.
Poster Session: P5-03-03 - Variant Classification Discordance: A real-world experience of genetic test results in a community-based setting
Among the Myriad products highlighted in the company’s SABCS exhibit are:
Follow Myriad on Twitter via @myriadgenetics and keep up to date with SABCS meeting news and updates by using the #SABCS22 hashtag.
About Myriad Genetics
Myriad, the Myriad logo, BRACAnalysis, BRACAnalysis CDx, Colaris, Colaris AP, MyRisk, Myriad MyRisk, MyRisk Hereditary Cancer, MyChoice CDx, Prequel, Prequel with Amplify, Amplify, Foresight, Precise, FirstGene, SneakPeek, Health.Illuminated., RiskScore, Prolaris, UroSuite, GeneSight, and EndoPredict are trademarks or registered trademarks.
Safe Harbor Statement